Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
about
Benign prostatic hyperplasia and new treatment options - a critical appraisal of the UroLift systemMinimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology updateA Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic HyperplasiaHolmium laser enucleation of the prostate: patient selection and perspectivesUroLift: a new minimally-invasive treatment for benign prostatic hyperplasiaLower urinary tract symptoms in men.Effect of an employer-sponsored health and wellness program on medical cost and utilization.Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature.Prostatic urethral lift: A minimally invasive treatment for benign prostatic hyperplasia.New intraprostatic injectables and prostatic urethral lift for male LUTS.Urolift: a New Face of Minimally Invasive Surgical Technique for Benign Prostatic Hyperplasia?Prostatic Urethral Lift Versus Transurethral Resection of the Prostate (TURP).24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham.Urolift - minimally invasive surgical BPH management.Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature.Medium-term efficacy of the prostatic urethral liftOptimizing the management of benign prostatic hyperplasia.Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
P2860
Q26747709-A08956F5-AC6E-4C7F-B166-19309E21BED7Q26796381-4C452477-FC3B-43E1-B471-1DD1B0D2E067Q27021610-185E3293-69A1-4AB3-B4E2-7C2D0A048B1CQ28072328-7E5C55AA-4C56-44EC-9332-579B4E40CFF5Q28074920-0949EBD7-212C-47CB-AF58-04EA90D6E7F5Q35225398-209DDE56-45D2-4AFE-8B4B-0D35A624136AQ37442673-670967DF-3DA9-42DB-B5BC-ABE99B87BA68Q38116465-6F320299-073A-4CB1-AAB1-688352D49F97Q38544310-17B06753-5267-40E0-810A-3ED3720669FFQ38551294-76B679C2-104A-4E37-90EA-887CD80EC907Q38901794-FB76B7CA-B2B0-49D5-99F8-6CFD087A12EEQ39150636-D3D457A4-2E8B-458C-B531-FDF40F007CA4Q39165097-DC82F642-4118-46BF-9277-1CAC1391504CQ39166801-FD45D173-806F-42C7-BCA5-5E7AEBC94262Q39198851-9DE4E7E3-722A-4829-9498-9DFF6D448B22Q39207960-FBD9B2E9-75C1-4E6B-BFC8-D3E1F73A1758Q39369510-2C398F69-6DD6-4A63-92F4-D73570A2ABA4Q41096890-6E453711-81F7-4FE2-A22E-29AA71E4586CQ41786747-C02D119C-458F-4181-8353-558BDFD6B090Q42321749-970D0418-4DF8-42F8-A18B-0EFBD97B6637Q47712228-3E19D76E-AA09-449C-A99C-7FD4D49F45E1
P2860
Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Safety and feasibility of the ...... n prostatic hyperplasia (BPH).
@en
Safety and feasibility of the ...... n prostatic hyperplasia (BPH).
@nl
type
label
Safety and feasibility of the ...... n prostatic hyperplasia (BPH).
@en
Safety and feasibility of the ...... n prostatic hyperplasia (BPH).
@nl
prefLabel
Safety and feasibility of the ...... n prostatic hyperplasia (BPH).
@en
Safety and feasibility of the ...... n prostatic hyperplasia (BPH).
@nl
P2093
P2860
P1433
P1476
Safety and feasibility of the ...... gn prostatic hyperplasia (BPH)
@en
P2093
Claus G Roehrborn
Harcharan S Gill
Henry H Woo
Mark K Plante
Peter T Chin
Reginald C Bruskewitz
P2860
P356
10.1111/J.1464-410X.2011.10342.X
P577
2011-05-06T00:00:00Z